Infiltrating Tumor Border Configuration is a Poor Prognostic Factor in Stage II and III Colon Adenocarcinoma.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
10
07
2020
accepted:
03
10
2020
pubmed:
27
10
2020
medline:
18
5
2021
entrez:
26
10
2020
Statut:
ppublish
Résumé
Tumor border configuration (TBC) is a prognostic factor in colorectal adenocarcinoma; however, the significance of TBC is not well-documented in colon adenocarcinoma alone. Our aim was to study the effect of TBC on overall and disease-free survival in stage II and III colon adenocarcinoma. We included patients with stage II and III colon adenocarcinoma who were surgically treated at a tertiary medical center between 2004 and 2015, to ensure long-term follow-up. Patients were stratified into four groups based on stage and TBC. A Cox regression was used to model the relationship of groups while accounting for relevant confounders. The cohort consisted of 700 patients (371 stage II and 329 stage III). Infiltrating TBC was statistically significantly associated with stage (p < 0.001) and extramural vascular invasion (p < 0.001), but not histologic grade (p = 0.7). Compared with pushing TBC, infiltrating TBC increased the hazard of death by a factor of 1.8 [95% confidence interval (CI) 1.4-2.4; p < 0.001] and 1.7 (95% CI 1.3-2.2; p < 0.001). The hazard of death in patients with stage II disease (infiltrating TBC) or stage III disease (pushing TBC) was not significantly different (adjusted hazard ratio 1.1, 95% CI 0.7-1.7; p = 0.8). Infiltrating TBC is a high-risk feature in patients with stage II and III colon adenocarcinoma. Stage II disease patients with infiltrating TBC and who are node-negative should be considered for adjuvant chemotherapy.
Identifiants
pubmed: 33105502
doi: 10.1245/s10434-020-09281-0
pii: 10.1245/s10434-020-09281-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3408-3414Références
Siegel R, Miller K, Fedwea S, Ahnen D, Meester R, Barzi A, et al. Colorectal cancer statistics, 2017. CA A Cancer J Clin. 2017;67(3):177–93.
Edge SB, Compton CC. The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.
Benson AB III, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408–19. https://doi.org/10.1200/jco.2004.05.063 .
doi: 10.1200/JCO.2004.05.063
pubmed: 15199089
Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2005;22(10):1797–806.
doi: 10.1200/JCO.2004.09.059
Babaei M, et al. Administration of adjuvant chemotherapy for stage II–III colon cancer patients: a European population-based study. Int J Cancer. 2018;142(7):1480–9.
doi: 10.1002/ijc.31168
Sargent D, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27(6):872–77.
doi: 10.1200/JCO.2008.19.5362
Jass JR, Atkin WS, Cuzick J, Bussey HJ, Morson BC, Northover JM, et al. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology. 1986;10(5):437–59. https://doi.org/10.1111/j.1365-2559.1986.tb02497 .
doi: 10.1111/j.1365-2559.1986.tb02497
pubmed: 3721406
Shepherd NA, Saraga EP, Love SB, Jass JR. Prognostic factors in colonic cancer. Histopathology. 1989;14(6):613–20.
doi: 10.1111/j.1365-2559.1989.tb02202.x
Morikawa T, Kuchiba A, Qian ZR, et al. Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. Ann Surg Oncol. 2012;19:1944–53.
doi: 10.1245/s10434-011-2174-5
Zlobec I, Baker K, Minoom P, Hayashi S, Terracciano L, Lugli A. Tumor border configuration added to TNM better stratifies stage II colorectal cancer patients into prognostic subgroups. Cancer 2009;115(17):4021–9.
doi: 10.1002/cncr.24450
Zlobec I, Holler S, Tornillo L, Terracciano L, Lugli A. Combined histomorphologic and immunohistochemical phenotype to predict the presence of vascular invasion in colon cancer. Dis Colon Rectum. 2009;52(6):1114–21.
doi: 10.1007/DCR.0b013e31819eefd9
Cianchi F, Messerini L, Palomba A, Boddi V, Perigli G, Pucciani F, et al. Character of the invasive margin in colorectal cancer: does it improve prognostic information of Dukes staging? Dis Colon Rectum. 1997;40(10):1170–5.
doi: 10.1007/BF02055162
National Comprehensive Cancer Network Board. NCCN Guidelines for Patients: Colon Cancer. National Comprehensive Cancer Network; 2017. p. 1–80.
Leijssen LGJ, Dinaux AM, Amri R, Taylor MS, Deshpande V, Bordeianou LG, et al. Impact of intramural and extramural vascular invasion on stage II–III colon cancer outcomes. J Surg Oncol. 2019;119(6):749–57.
doi: 10.1002/jso.25367
Wang LM, Kevans D, Mulcahy H, O’Sullivan J, Fennelly D, Hyland J, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol. 2009;33(1):134–41.
doi: 10.1097/PAS.0b013e318184cd55
Egashira Y, Yoshida T, Hirata I, et al. Analysis of pathological risk factors for lymph node metastasis of submucosal invasive colon cancer. Mod Pathol. 2004;17:503–11.
doi: 10.1038/modpathol.3800030